Enterome Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 78

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $19M

  • Investors
  • 17

Enterome General Information

Description

Developer of pharmaceuticals and diagnostic tests designed for developing off-the-shelf, transformational cancer treatments targeting all tumor types. The company's approach generates a powerful, long-lasting immune response from the patient's own effector memory T-cells, overcoming the immune tolerance to self-antigens, integrated with a research and development platfo, with therm potential to deliver multiple candidates with a rapid progression, overcoming the immune tolerance to self-antigens, enabling healthcare companies to begin treatment more quickly and resulting in a likelihood of successful treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 94/96 avenue Ledru-Rollin
  • 75011 Paris
  • France
+33 01
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 94/96 avenue Ledru-Rollin
  • 75011 Paris
  • France
+33 01

Enterome Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Enterome Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Later Stage VC 12-Jun-2025 $19M Completed Clinical Trials - Phase 2
12. Accelerator/Incubator 30-Oct-2023 Completed Clinical Trials - Phase 2
11. Later Stage VC (Series F) 25-Oct-2023 Completed Clinical Trials - Phase 2
10. Accelerator/Incubator 11-May-2023 Completed Clinical Trials - Phase 2
9. Later Stage VC 19-Jul-2022 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series E) 25-Jun-2020 Completed Clinical Trials - Phase 1
7. Later Stage VC 23-Oct-2018 Completed Clinical Trials - Phase 1
6. Later Stage VC (Series D) 23-Nov-2017 Completed Clinical Trials - Phase 1
5. Later Stage VC (Series C) 20-Apr-2016 $16.4M $42.3M Completed Clinical Trials - Phase 1
4. Later Stage VC (Series B) 01-May-2014 $13.8M $25.9M Completed Startup
To view Enterome’s complete valuation and funding history, request access »

Enterome Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
P3 Shares
Ordinary
P3 Shares
P2 Shares
P2 Shares
P2 Shares
P1 Shares 3,750,000 $0.392203 $2.06 $2.06 1x $2.06 19.38%
P Shares 825,000 $0.392203 $1.88 $1.88 1x $1.88 4.26%
To view Enterome’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Enterome Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of pharmaceuticals and diagnostic tests designed for developing off-the-shelf, transformational cancer treatme
Drug Discovery
Paris, France
78 As of 2024

Paris, France
 

Leeds, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Enterome Competitors (34)

One of Enterome’s 34 competitors is Mnemo Therapeutics, a Venture Capital-Backed company based in Paris, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mnemo Therapeutics Venture Capital-Backed Paris, France
4D pharma Corporation Leeds, United Kingdom
SynDevRx Venture Capital-Backed Cambridge, MA
Biotecnol Formerly VC-backed London, United Kingdom
Iovance Biotherapeutics Corporation San Carlos, CA
You’re viewing 5 of 34 competitors. Get the full list »

Enterome Patents

Enterome Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4499678-A1 Antigenic peptides for prevention and treatment of cancer Pending 31-Mar-2022
US-20250205324-A1 Antigenic peptides for prevention and treatment of cancer Pending 31-Mar-2022
WO-2023187127-A1 Antigenic peptides for prevention and treatment of cancer Inactive 31-Mar-2022
AU-2023246941-A1 Antigenic peptides for prevention and treatment of cancer. Pending 31-Mar-2022
AU-2022318248-A1 Il-10 inducing polypeptides and uses thereof Active 27-Jul-2021 C07K14/245
To view Enterome’s complete patent history, request access »

Enterome Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Enterome Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
Institute for Follicular Lymphoma Innovation Not-For-Profit Venture Capital Minority
Nestlé Corporation Minority
Primo Capital (Milano) Venture Capital Minority
Therapy Acceleration Program (TAP) Not-For-Profit Venture Capital Minority
Matwin Accelerator/Incubator
You’re viewing 5 of 17 investors. Get the full list »

Enterome Investments (1)

Enterome’s most recent deal was a Joint Venture with Microbiome Diagnostics Partners. The deal was made on 11-Jul-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Microbiome Diagnostics Partners 11-Jul-2017 Joint Venture Diagnostic Equipment
To view Enterome’s complete investments history, request access »

Enterome FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process